Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Observational Model: Case-Only, Time Perspective: Prospective
Evaluation of tolerability of treatment on a 4 point scale
Last Visit (after at least 180 days of treatment)
Astellas Pharma Europe B.V.
Belgium: Ethics Committee